Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFOX6 ± Citrus Flavonoid Tablets (Alvenor) in YWHAB-High Locally Advanced Rectal Cancer
ChiCTR2500107086Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mFOLFOX6 and micronized purified flavonoid fraction in rectal adenocarcinoma (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Tumor downstaging rate (ypTNM stage 0–I). Started Aug 2025; status: recruiting.
02
Drugs
mFOLFOX6micronized purified flavonoid fraction
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500107086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107086.